UNITED STATES
NUCLEAR REGULATORY COMMISSION
REGION I
475 ALLENDALE ROAD
KING OF PRUSSIA, PENNSYLVANIA 19406-1415

January 10, 2005

Docket No. 03002578 License No. 29-13911-01
Control No. 135971

Wayne C. Schiffner
Executive Vice President
South Jersey Healthcare - Regional Medical Center
1505 W. Sherman Avenue
Vineland, NJ 08360

SUBJECT: SOUTH JERSEY HEALTHCARE - REGIONAL MEDICAL CENTER, ISSUANCE OF LICENSE AMENDMENT, CONTROL NO. 135971

Dear Mr. Schiffner:

This refers to your license amendment request. Enclosed with this letter is the amended license. The South Jersey Healthcare Bridgeton facility, located at 333 Irving Avenue, Bridgeton, New Jersey, and the South Jersey Healthcare Newcomb facility, located at 65 South State Street, Vineland, New Jersey, may be released for unrestricted use.

Please review the enclosed document carefully and be sure that you understand and fully implement all the conditions incorporated into the amended license. If there are any errors or questions, please notify the U.S. Nuclear Regulatory Commission, Region I Office, Licensing Assistance Team, (610) 337-5239, so that we can provide appropriate corrections and answers.

An environmental assessment for this action is not required, since this action is categorically excluded under 10 CFR 51.22(c)(14).

Please note that on October 25, 2004, the NRC suspended public access to ADAMS, and initiated an additional security review of publicly available documents to ensure that potentially sensitive information is removed from the ADAMS database accessible through the NRC's web site. Interested members of the public may obtain copies of the referenced documents for review and/or copying by contacting the NRC Public Document Room pending resumption of public access to ADAMS. The NRC Public Document Room is located at NRC Headquarters in Rockville, MD, and can be contacted at 800-397-4209 or 301-415-4737 or pdr@nrc.gov.

Thank you for your cooperation.

Sincerely,

Original signed by Michelle Beardsley

Michelle Beardsley
Health Physicist
Medical Branch
Division of Nuclear Materials Safety

Enclosure:
Amendment No. 52

cc:
Paul J. Chase, D.O., Radiation Safety Officer

DOCUMENT NAME: P:\I29-13911-01.135971.01212005.wpd

To receive a copy of this document, indicate in the box: "**C**" = Copy w/o attach/encl "**E**" = Copy w/ attach/encl "**N**" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	N	DNMS/RI			
NAME	MSimmons/MRS5		MBeardsley/MRB					
DATE	1/10/05		1/10/05					

OFFICIAL RECORD COPY

Amendment No. 52

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	In accordance with the letters dated October 29, 2004 and November 15, 2004
1. South Jersey Healthcare - Regional Medical Center Department of Radiology 2. 1505 W. Sherman Avenue Vineland, New Jersey 08360	3. License number 29-13911-01 is amended in its entirety to read as follows: 4. Expiration date October 31, 2013 5. Docket No. 03002578 Reference No. 29-03438-01/29-16384-01

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Any byproduct material permitted by 10 CFR 35.100	A. Any	A. As needed
B. Any byproduct material permitted by 10 CFR 35.200	B. Any	B. As needed
C. Any byproduct material permitted by 10 CFR 35.300	C. Any	C. 3.3 curies
D. Any byproduct material permitted by 10 CFR 35.400	D. Sealed Sources (3M Models 6501-6503, CD6C-CA; Amersham Model 6711; IPL Model 6500 series)	D. 2 curies
E. Any byproduct material permitted by 10 CFR 31.11	E. Prepackaged Kits	E. 3 millicuries
F. Cesium 137	F. Sealed sources (Amersham Model 773)	F. 150 millicuries

9. Authorized use:Isotope Product Laboratories

A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
B. Any imaging and localization study permitted by 10 CFR 35.200.
C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.
D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.
E. In vitro studies.
F. Calibration of the licensee's instruments.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-13911-01

Docket or Reference Number
030-02578/29-03438-01/29-16384-01

Amendment No. 52

CONDITIONS

10. A. Only licensed material listed in 6.C. and 6.F. may be used or stored at the licensee's facilities located at the Millville facility, 1200 North High Street, Millville, New Jersey.

    B.. Only licensed material listed in 6.A., 6.B., and 6.C. for diagnostic studies or therapy procedures except those procedures where the patient cannot be immediately released in accordance with 10 CFR 35.75, and 6.E., may be used or stored at the licensee's facilities located at the Elmer facility, West Front Street, Elmer, New Jersey.

    C. Licensed materials listed in 6.A. - 6.F., may be used or stored at the licensee's facilities located at 1505 West Sherman Avenue, Vineland, New Jersey.

11. The Radiation Safety Officer for this license is Paul J. Chase, D.O.

12. Licensed material is only authorized for use by, or under the supervision of:

    A. Individuals permitted to work as an authorized user and/or authorized nuclear pharmacist in accordance with 10 CFR 35.13 and 35.14.

    B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
Richard E. Beck, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Paul J. Chase, D.O.	35.100; 35.200; 35.300
Joseph W. Fanelle, M.D.	35.300; 35.400; Cesium 137 for instrument calibrations
Barry E. Shapiro, D.O.	35.200
Michael K. Dovnarsky, M.D.	35.200
Steven H. Rothfarb, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Craig Taylor, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-13911-01

Docket or Reference Number
030-02578/29-03438-01/29-16384-01

Amendment No. 52

Authorized Users	Material and Use
Glenda R. Smith, M.D.	35.300; 35.400;
Michael Villani, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Steven M. Cohn, M.D.	35.200
Michael Spivak, D.O.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Ernesto Go, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
Satish P. Shah, M.D.	35.100; 35.200; 35.300, except thyroid carcinoma
David I. Olian, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies; In vitro studies
Michael Ramer, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; In vitro studies
Makbul M. Kureshi, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction
Steven Singer, M.D.	35.100; 35.200; Oral administration of sodium Iodide Iodine-131 for imaging and localization studies; In vitro studies
Robert M. Sheiman, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies; In vitro studies
Marc L. Baum, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies; In vitro studies
Anil Desai, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; In vitro studies

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-13911-01

Docket or Reference Number
030-02578/29-03438-01/29-16384-01

Amendment No. 52

Authorized Users	Material and Use
Jeffrey Larkin, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies; In vitro studies
Markus Whitley, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies and treatment of hyperthyroidism and cardiac dysfunction; In vitro studies
Sloan Rosten, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Jay Patel, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Sherrill Little, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Lewis K. Marchant, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Scott George Mattox, M.D.	35.100; 35.200; Oral administration of sodium iodide iodine-131 for imaging and localization studies
Shailendra A. Desai, M.D.	35.100; 35.200
Steven L. Gilbert, M.D.	35.100; 35.200
Dearon K. Tufankjian, D.O.	35.100; 35.200

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

14. Sealed sources or detector cells containing licensed material shall not be opened or sources removed from source holders by the licensee.

15. The licensee shall conduct a physical inventory every six months, or at other intervals approved by the U.S. Nuclear Regulatory Commission, to account for all sources and/or devices received and possessed under the license.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-13911-01

Docket or Reference Number
030-02578/29-03438-01/29-16384-01

Amendment No. 52

16. For sealed sources not associated with 10 CFR Part 35 use, the following conditions apply:

    A. Sealed sources shall be tested for leakage and/or contamination at intervals not to exceed the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State.

    B. In the absence of a certificate from a transferor indicating that a leak test has been made within the intervals specified in the certificate of registration issued by the U.S. Nuclear Regulatory Commission under 10 CFR 32.210 or under equivalent regulations of an Agreement State, prior to the transfer, a sealed source received from another person shall not be put into use until tested and the test results received.

    C. Sealed sources need not be tested if they are in storage and are not being used; however, when they are removed from storage for use or transferred to another person and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

    D. The leak test shall be capable of detecting the presence of 0.005 microcurie (185 becquerels) of radioactive material on the test sample. If the test reveals the presence of 0.005 microcurie (185 becquerels) or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission in accordance with 10 CFR 30.50(c)(2), and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations.

    E. Tests for leakage and/or contamination, including leak test sample collection and analysis, shall be performed by the licensee or by other persons specifically licensed by the U.S. Nuclear Regulatory Commission or an Agreement State to perform such services.

17. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number
29-13911-01

Docket or Reference Number
030-02578/29-03438-01/29-16384-01

Amendment No. 52

18. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

    A. Application dated June 30, 2003
    B. Letter dated April 5, 2004
    C. Letter dated July 6, 2004

For the U.S. Nuclear Regulatory Commission

Date January 10, 2005
bbbbbbbbbbbbbbbbbbbbbbb

By ***Original signed by Michelle Beardsley***

Michelle Beardsley
Medical Branch
Division of Nuclear Materials Safety
Region I
King of Prussia, Pennsylvania 19406